Clinical management of BRCA1 and BRCA2 mutation ca...[Oncogene. 2006]

Search for

Advanced Search (beta)

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 1

Click to change filter selection through MyNCBI.

1: Oncogene. 2006 Sep 25;25(43):5825-31. Links

Clinical management of BRCA1 and BRCA2 mutation carriers.

Domchek SM, Weber BL.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. susan.domchek@uphs.upenn.edu

The cancer susceptibility genes BRCA1 and BRCA2 appear to be responsible for virtually all hereditary breast ovarian families, and a smaller subset of hereditary site-specific breast cancer families. Fortunately, effective strategies have been developed to reduce the risk for the development of breast and ovarian cancer in women with BRCA1/2 mutations, making genetic testing for these mutations an important part of the management at women with a strong family history of these diseases. Here, we review the current evidence for risk reduction strategies and outline future research directions.

PMID: 16998496 [PubMed - indexed for MEDLINE]

Perspectives in the clinical management of BRCA mutations carriers. [J Exp Clin Cancer Res. 2002]
The clinical management of BRCA1 and BRCA2 mutation carriers. [Curr Oncol Rep. 2008]
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. [JAMA. 2005]
[Hereditary breast and ovarian cancer: primary and secondary prevention for BRCA1 and BRCA2 mutation carriers] [Med Clin (Barc). 2007]
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. [J Obstet Gynaecol Can. 2007]
» See all Related Articles...

Display Show

Clinical management of BRCA1 and BRCA2 mutation carriers.

Related Articles